GlaxoSmithKline Gets Exclusive Rights To Medivir's Xerclear
23rd Jun 2010 07:42
LONDON (Dow Jones)--GlaxoSmithKline PLC (GSK), a research-based pharmaceutical and healthcare firm, and Medivir (MVIR-B.SK) Wednesday announced an exclusive agreement for the commercialization of cold sore treatment, Xerclear (acyclovir and hydrocortisone) for non-prescription use in key global mark
Read moreNICE Rebuffs Glaxo's Drug Arzerra On Cost, Lack Of Data
23rd Jun 2010 00:01
By Sten Stovall Of DOW JONES NEWSWIRES LONDON (Dow Jones)--The U.K.'s National Institute for Health and Clinical Excellence, or NICE, said Thursday it won't recommend publicly-funded use of GlaxoSmithKline PLC's (GSK) leukaemia drug Arzerra, due to lack of data and proof the medicine offers v
Read moreEuropean Pharma, Governments Need New Dialogue - Glaxo CEO
21st Jun 2010 16:17
By Sten Stovall Of DOW JONES NEWSWIRES LONDON (Dow Jones)--Europe's research-based pharmaceuticals industry Monday called for "a new dialogue" with cash-strapped governments to avoid a damaging downward trend in product innovation and health care provision, as countries in the region grapple
Read moreBayer Gets US Approval For Staxyn Tablets
21st Jun 2010 08:32
FRANKFURT (Dow Jones)--German pharmaceutical and chemicals company Bayer AG (BAYN.XE) said Monday that it has received U.S. approval for Staxyn, a new formulation of its erectile dysfunction treatment Levitra. MAIN FACTS: -Staxyn is a tablet that disintegrates on the tongue without liquid.
Read moreLondon close: Winning streak comes to an end
18th Jun 2010 16:44
Hopes of Footsie making it eight days of rises in a row were dashed at the death. Leaders outnumbered laggards among FTSE 100 stocks but with BP giving up the gains of the morning after a downgrade from debt ratings agency Moody's the blue-chip index ended marginally easier on the day. BP, for once
Read moreMARKET TALK: Genmab Closes Up On Renewed Bid Speculation
18th Jun 2010 16:21
1521 GMT [Dow Jones] Genmab (GEN.KO) closes +19% at DKK61 amid renewed speculation that partner GlaxoSmithKline (GSK) could place a bid for the company, says Sydbank's head of Scandinavian equities Ole Jensen. Says the stock has been very volatile since CEO Drakeman unexpectedly left the company ear
Read moreFTSE 100 movers: Miners move higher
18th Jun 2010 15:19
Footsie has edged higher with mining companies leading the push higher. Miners Fresnillo, Lonmin and Randgold Resources are all higher. BT is lower due to worries about a potential strike. The Communication Workers Union wants BT to increase its 2% pay offer. UBS has cut its ratings for outso
Read moreCORRECT(06/17):ViiV Healthcare,Amfar In Asia HIV Treatment Pact
18th Jun 2010 11:26
("GlaxoSmithKline, Amfar Form Pact To Optimize HIV Treatment In Asia," at 1305 GMT Thursday, incorrecly said GlaxoSmithKline and Amfar had formed a pact in the lead and headline. The correct version follows:) LONDON (Dow Jones)--ViiV Healthcare and amfAR Thursday announce a two year partnership
Read moreGlaxoSmithKline, Amfar Form Pact To Optimize HIV Treatment In Asia
17th Jun 2010 14:09
LONDON (Dow Jones)--Pharmaceutical giant GlaxoSmithKline PLC (GSK) and amfAR Thursday announce a two year partnership that aims to improve access and optimize the quality of healthcare for infants and children living with HIV across Asia. MAIN FACTS: -$2 million initiative created to generat
Read moreUPDATE: Consort Medical Sees New Products Driving Growth
17th Jun 2010 11:59
(Adds executive and analyst comment.) By Jason Douglas Of DOW JONES NEWSWIRES LONDON (Dow Jones)--Medical device company Consort Medical PLC (CSRT.LN) Thursday reported a 13% decline in fiscal year profit, hurt by lower sales and a restructuring, but said new products like an automatic i
Read moreGlaxo, Human Genome: Benlysta Meets Late-Stage Trial Endpoint
17th Jun 2010 10:33
LONDON (Dow Jones)--GlaxoSmithKline Plc (GSK) and U.S.-based partner Human Genome Sciences Inc. (HGSI) Thursday said their jointly-developed experimental drug Benlysta met its primary endpoint in a late-stage clinical study, further boosting its potential to become the first new treatment in 50 year
Read moreUPDATE: Merck: FDA Extends Review Of Gardasil Use By Older Women
16th Jun 2010 21:41
(Updates to include more details about studies of Gardasil beginning in 8th paragraph.) By Peter Loftus Of DOW JONES NEWSWIRES The U.S. Food and Drug Administration has extended its review of Merck & Co.'s (MRK) application to broaden use of cervical-cancer vaccine Gardasil to include ol
Read moreCORRECT: Merck: FDA Extends Review Of Gardasil's Use By Older Women
16th Jun 2010 20:25
("Merck: FDA Extends Review Of Gardasil's Use By Older Women" published at 3:06 pm EDT incorrectly stated in the seventh paragraph Merck hasn't publicly released results of a Gardasil study. Merck released the data in February. A corrected version follows.) By Peter Loftus Of DOW JONES NEWSWIR
Read moreIN THE PIPELINE: Progress Seen In Battle Against Skin Cancer
16th Jun 2010 12:35
(This article was originally published Tuesday.) By Peter Loftus Of DOW JONES NEWSWIRES Recent research is raising hope that new drugs are on the horizon that could prolong the lives of people with the most serious form of skin cancer. The experimental drugs aren't cures, and the lo
Read moreMARKET TALK: UBS Upgrades European Tech Hardware, Software
16th Jun 2010 09:53
0853 GMT [Dow Jones] UBS upgrades the European ex-UK tech hardware sector to overweight from underweight, given attractive valuations. Says relative earnings momentum is already at a record low, and "it is hard to see it getting much worse." Also upgrades software to overweight from neutral, as a pl
Read more